Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Massimo Lemoli

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Haematologica|November 20, 2023
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agentsRoberto Mina, Maria Teresa Petrucci, Francesca Bonello, et al.
Journal of Translational Medicine|August 7, 2019
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their functionFrancesca Ulbar, Tiziana Montemurro, Tatiana Jofra, et al.
Cell Reports|June 21, 2025
Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitorsFrancesco Ravera, Martina Dameri, Isabella Lombardo, et al.
Blood Advances|December 11, 2024
NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myelomaDebora Soncini, Pamela Becherini, Francesco Ladisa, et al.
Hemasphere|September 4, 2023
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMAFabio Efficace, Wael Al Essa, Uwe Platzbecker, et al.
Frontiers in Immunology|November 22, 2021
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK CellsFabio Guolo, Paola Minetto, Silvia Pesce, et al.
Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Cancer Medicine|October 29, 2019
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysisEnrico Balleari, Rosa Angela Filiberti, Chiara Salvetti, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2024
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment PlanMichele Malagola, Alessandra Iurlo, Cristina Bucelli, et al.
Blood Cancer Journal|October 7, 2020
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use programFabio Guolo, Luana Fianchi, Paola Minetto, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Haematologica|November 20, 2023
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agentsRoberto Mina, Maria Teresa Petrucci, Francesca Bonello, et al.
Journal of Translational Medicine|August 7, 2019
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their functionFrancesca Ulbar, Tiziana Montemurro, Tatiana Jofra, et al.
Cell Reports|June 21, 2025
Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitorsFrancesco Ravera, Martina Dameri, Isabella Lombardo, et al.
Blood Advances|December 11, 2024
NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myelomaDebora Soncini, Pamela Becherini, Francesco Ladisa, et al.
Hemasphere|September 4, 2023
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMAFabio Efficace, Wael Al Essa, Uwe Platzbecker, et al.
Frontiers in Immunology|November 22, 2021
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK CellsFabio Guolo, Paola Minetto, Silvia Pesce, et al.
Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Cancer Medicine|October 29, 2019
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysisEnrico Balleari, Rosa Angela Filiberti, Chiara Salvetti, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2024
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment PlanMichele Malagola, Alessandra Iurlo, Cristina Bucelli, et al.
Blood Cancer Journal|October 7, 2020
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use programFabio Guolo, Luana Fianchi, Paola Minetto, et al.
Pageof 5